A marine-derived compound, abalone hemocyanin, from Haliotis rubra was shown to have a unique mechanism of antiviral activity against herpes simplex virus 1 (HSV-1) infections. In vitro assays demonstrated the dose-dependent and inhibitory effect of purified hemocyanin against HSV-1 infection in Vero cells with a 50% effective dose (ED 50 ) of 40 to 50 nM and no significant toxicity. In addition, hemocyanin specifically inhibited viral attachment and entry by binding selectively to the viral surface glycoproteins gD, gB, and gC, probably by mimicking their receptors. However, hemocyanin had no effect on postentry events and did not block infection by binding to cellular receptors for HSV. By the use of different mutants of gD and gB and a competitive heparin binding assay, both protein charge and conformation were shown to be the driving forces of the interaction between hemocyanin and viral glycoproteins. These findings also suggested that hemocyanin may have different motifs for binding to each of the viral glycoproteins B and D. The dimer subunit of hemocyanin with a 10-fold-smaller molecular mass exhibited similar binding to viral surface glycoproteins, showing that the observed inhibition did not require the entire multimer. Therefore, a small hemocyanin analogue could serve as a new antiviral candidate for HSV infections.T he predominant antiviral therapies for herpes simplex virus (HSV) infections are nucleoside analogue inhibitors, such as acyclovir, its prodrug valacyclovir, famciclovir (a prodrug of penciclovir), and the second line of drugs for resistant virus, foscarnet and cidofovir. These drugs are all inhibitors of viral DNA polymerase (1). The variety is limited despite the fact that HSV has more than 80 genes that are required for its functionality and, therefore, could potentially be targeted by multiple types of inhibitors (2). Thus, improving the efficacy of current HSV treatment relies on the discovery of new antiviral compounds targeting various functions of the virus, preferably earlier stages of the HSV viral life cycle such as viral attachment and entry. Viral attachment and entry are regulated by surface glycoproteins gC, gB, gD, and gH-gL (3, 4). Attachment is a two-step process involving the primary interaction of gC and/or gB with heparan sulfate proteoglycans (HSPG), followed by the secondary gD-mediated binding to its receptors, such as herpesvirus entry mediator (HVEM), nectin-1, or 3-O-sulfated heparan sulfate. This interaction triggers the activation of gH-gL and gB, which leads to the fusion of viral envelope and plasma membrane of the host cell either at the surface or in the endosomes (3, 4). Many steps in the entry process of HSV remain unclear; however, it is known that gD determines HSV tropism and that the conformational changes in gD upon binding to its receptors are critical in triggering an activation cascade (5, 6).Viral attachment or entry could be inhibited by mimicking cellular receptors that are involved in these events. For example, heparin interacts with HSPG bi...